Skip to main content
Erschienen in: Heart and Vessels 6/2017

27.12.2016 | Original Article

The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study

verfasst von: Christian Bosseau, Erwan Donal, Lars H. Lund, Emmanuel Oger, Camilla Hage, Geneviève Mulak, Jean-Claude Daubert, Cecilia Linde, On behalf of the KaRen investigators

Erschienen in: Heart and Vessels | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

The prognostic value of atrial fibrillation (AF) in heart failure with preserved ejection fraction (HFPEF) remains controversial. We sought to study the prognostic value of AF in a prospective cohort and to characterize the HFPEF patients with AF. KaRen was a prospective, multicenter, international, observational study intended to characterize HFPEF; 538 patients presenting with an acute decompensated cardiac failure and a left ventricular EF > 45% were included. EKG and echocardiogram performed 4–8 week following the index hospitalization were analyzed in core centers. Clinical and echocardiographic characteristics of patients in sinus rhythm vs. with documented AF at enrolment (decompensated HF), upon their 4–8-week visit (in presumed stable clinical condition) and according to patients’ cardiac history, were compared. The primary study endpoint was death from any cause or first hospitalization for decompensated heart failure (HF). A total of 413 patients (32% in AF) were analyzed, with a mean follow-up period of 28 months. The patients were primarily elderly individuals (mean age: 76.2 years), with a slight female predominance and a high prevalence of non-cardiovascular comorbidities. The baseline echocardiographic characteristics and the natriuretic peptide levels were indicative of a more severe heart condition among the patients with AF. However, the patients with AF exhibited a similar survival-free interval compared with the patients in sinus rhythm. In this elderly HFPEF population with a high prevalence of non-cardiovascular comorbidities, the presence of AF was not associated with a worse prognosis despite impaired clinical and echocardiographic features.
ClinicalTrials.gov: NCT00774709.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death—the Framingham heart study. Circulation 98:946–952CrossRefPubMed Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death—the Framingham heart study. Circulation 98:946–952CrossRefPubMed
2.
Zurück zum Zitat Pedersen OD, Bagger H, Kober L, Torp-Pedersen C (1999) The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 20(10):748–754CrossRefPubMed Pedersen OD, Bagger H, Kober L, Torp-Pedersen C (1999) The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 20(10):748–754CrossRefPubMed
3.
Zurück zum Zitat Nilsson KR Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ (2010) Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 96(11):838–842CrossRefPubMed Nilsson KR Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ (2010) Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 96(11):838–842CrossRefPubMed
4.
Zurück zum Zitat Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA, Investigators CHARM (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am College Cardiol 47(10):1997–2004CrossRef Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA, Investigators CHARM (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am College Cardiol 47(10):1997–2004CrossRef
5.
Zurück zum Zitat Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26(13):1303–1308CrossRefPubMed Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26(13):1303–1308CrossRefPubMed
6.
Zurück zum Zitat Mulder BA, van Veldhuisen DJ, Crijns HJ, Bohm M, Cohen-Solal A, Babalis D, Roughton M, Flather MD, Coats AJ, Van Gelder IC (2012) Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail 14(10):1171–1178CrossRefPubMed Mulder BA, van Veldhuisen DJ, Crijns HJ, Bohm M, Cohen-Solal A, Babalis D, Roughton M, Flather MD, Coats AJ, Van Gelder IC (2012) Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail 14(10):1171–1178CrossRefPubMed
7.
Zurück zum Zitat Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23):2926–2931CrossRefPubMed Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23):2926–2931CrossRefPubMed
8.
Zurück zum Zitat Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, Ennezat PV, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C; KaRen Investigators (2014) Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail 16(9):992–1001 Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, Ennezat PV, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C; KaRen Investigators (2014) Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail 16(9):992–1001
9.
Zurück zum Zitat Donal E, Lund LH, Linde C, Edner M, Lafitte S, Persson H, Bauer F, Ohrvik J, Ennezat PV, Hage C, Löfman I, Juilliere Y, Logeart D, Derumeaux G, Gueret P (2009) Rationale and design of the Karolinska–Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail 11(2):198–204CrossRefPubMedPubMedCentral Donal E, Lund LH, Linde C, Edner M, Lafitte S, Persson H, Bauer F, Ohrvik J, Ennezat PV, Hage C, Löfman I, Juilliere Y, Logeart D, Derumeaux G, Gueret P (2009) Rationale and design of the Karolinska–Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail 11(2):198–204CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N England J Med 285(26):1441–1446CrossRef McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N England J Med 285(26):1441–1446CrossRef
11.
Zurück zum Zitat Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cardim NM, Cosyns B, Delgado V, Haugaa KH, Muraru D, Nieman K, Boriani G, Cohen A (2016) EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 17(4):355–383CrossRefPubMed Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cardim NM, Cosyns B, Delgado V, Haugaa KH, Muraru D, Nieman K, Boriani G, Cohen A (2016) EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 17(4):355–383CrossRefPubMed
12.
Zurück zum Zitat Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E (1999) Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 83(11):1544–1547CrossRefPubMed Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E (1999) Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 83(11):1544–1547CrossRefPubMed
13.
Zurück zum Zitat Grigorian Shamagian L, Roman AV, Seara JG, Sande JL, Veloso PR, Gonzalez-Juanatey JR (2006) Atrial fibrillation in patients hospitalized for congestive heart failure: The same prognostic influence independently of left ventricular systolic function? Int J Cardiol 110:366–372CrossRefPubMed Grigorian Shamagian L, Roman AV, Seara JG, Sande JL, Veloso PR, Gonzalez-Juanatey JR (2006) Atrial fibrillation in patients hospitalized for congestive heart failure: The same prognostic influence independently of left ventricular systolic function? Int J Cardiol 110:366–372CrossRefPubMed
14.
Zurück zum Zitat Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators (2006) Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 152(5):974.e7–974e11 Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators (2006) Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 152(5):974.e7–974e11
15.
Zurück zum Zitat Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26(13):1303–1308CrossRefPubMed Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26(13):1303–1308CrossRefPubMed
16.
Zurück zum Zitat Pai RG, Varadarajan P (2007) Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 30(7):349–354CrossRefPubMed Pai RG, Varadarajan P (2007) Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 30(7):349–354CrossRefPubMed
17.
Zurück zum Zitat Parkash R, Maisel WH, Toca FM, Stevenson G (2005) Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J 150(4):701–706CrossRefPubMed Parkash R, Maisel WH, Toca FM, Stevenson G (2005) Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J 150(4):701–706CrossRefPubMed
18.
Zurück zum Zitat Fung JW, Sanderson JE, Yip GW, Zhang Q, Yu CM (2007) Impact of atrial fibrillation in heartfailure with normal ejection fraction: clinical and echocardiographic study. J Card Fail 13(8):649–655CrossRefPubMed Fung JW, Sanderson JE, Yip GW, Zhang Q, Yu CM (2007) Impact of atrial fibrillation in heartfailure with normal ejection fraction: clinical and echocardiographic study. J Card Fail 13(8):649–655CrossRefPubMed
19.
Zurück zum Zitat Zakeri R, Chamberlain AM, Roger VL, Redfield MM (2013) Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128(10):1085–1093CrossRefPubMedPubMedCentral Zakeri R, Chamberlain AM, Roger VL, Redfield MM (2013) Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128(10):1085–1093CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Eapen ZJ, Greiner MA, Fonarow GC, Yuan Z, Mills RM, Hernandez AF, Curtis LH (2014) Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 167(3):369–375 e2 Eapen ZJ, Greiner MA, Fonarow GC, Yuan Z, Mills RM, Hernandez AF, Curtis LH (2014) Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 167(3):369–375 e2
21.
Zurück zum Zitat Rusinaru D, Leborgne L, Peltier M, Tribouilloy C (2008) Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction. Eur J Heart Fail 10(6):566–572CrossRefPubMed Rusinaru D, Leborgne L, Peltier M, Tribouilloy C (2008) Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction. Eur J Heart Fail 10(6):566–572CrossRefPubMed
22.
Zurück zum Zitat Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, Tsutsui H, Registry Japanese Cardiac, Of Heart Failure in Cardiology (2009) Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73(11):2084–2090CrossRefPubMed Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, Tsutsui H, Registry Japanese Cardiac, Of Heart Failure in Cardiology (2009) Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73(11):2084–2090CrossRefPubMed
23.
Zurück zum Zitat Linssen GC, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL, van Veldhuisen DJ (2011) Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13(10):1111–1120CrossRefPubMed Linssen GC, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL, van Veldhuisen DJ (2011) Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13(10):1111–1120CrossRefPubMed
24.
Zurück zum Zitat McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, Gurwitz JH, Goldberg RJ, Go AS; Cardiovascular Research Network PRESERVE Study (2013) Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2(1):e005694 McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, Gurwitz JH, Goldberg RJ, Go AS; Cardiovascular Research Network PRESERVE Study (2013) Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2(1):e005694
25.
Zurück zum Zitat Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D (2014) The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail 16(12):1317–1322CrossRefPubMed Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D (2014) The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail 16(12):1317–1322CrossRefPubMed
26.
Zurück zum Zitat Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll of Cardiol 59(11):998–1005CrossRef Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll of Cardiol 59(11):998–1005CrossRef
27.
Zurück zum Zitat Maréchaux S, Six-Carpentier MM, Bouabdallaoui N, Montaigne D, Bauchart JJ, Mouquet F, Auffray JL, Le Tourneau T, Asseman P, LeJemtel TH, Ennezat PV (2011) Heart Vessels 26:313CrossRefPubMed Maréchaux S, Six-Carpentier MM, Bouabdallaoui N, Montaigne D, Bauchart JJ, Mouquet F, Auffray JL, Le Tourneau T, Asseman P, LeJemtel TH, Ennezat PV (2011) Heart Vessels 26:313CrossRefPubMed
28.
Zurück zum Zitat Wasywich CA, Whalley GA, Gamble GD, Wright SP, Doughty RN (2006) Does rhythm matter? The prognostic importance of atrial fibrillation in heart failure. Heart Lung Circ 15(6):353–357CrossRefPubMed Wasywich CA, Whalley GA, Gamble GD, Wright SP, Doughty RN (2006) Does rhythm matter? The prognostic importance of atrial fibrillation in heart failure. Heart Lung Circ 15(6):353–357CrossRefPubMed
29.
Zurück zum Zitat Setoguchi M, Hashimoto Y, Sasaoka T, Ashikaga T, Isobe M (2015) Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction. Heart Vessels 5:595–603CrossRef Setoguchi M, Hashimoto Y, Sasaoka T, Ashikaga T, Isobe M (2015) Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction. Heart Vessels 5:595–603CrossRef
Metadaten
Titel
The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study
verfasst von
Christian Bosseau
Erwan Donal
Lars H. Lund
Emmanuel Oger
Camilla Hage
Geneviève Mulak
Jean-Claude Daubert
Cecilia Linde
On behalf of the KaRen investigators
Publikationsdatum
27.12.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 6/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0933-8

Weitere Artikel der Ausgabe 6/2017

Heart and Vessels 6/2017 Zur Ausgabe

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.